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Abstract
Superoxide dismutase 1 (SOD1) efficiently catalyzes dismutation of superoxide but its poor
delivery to the target sites in the body, such as brain, hinders its use as a therapeutic agent for
superoxide-associated disorders. Here to enhance the delivery of SOD1 across the blood brain
barrier (BBB) and in neurons the enzyme was conjugated with poly(2-oxazoline) (POx) block
copolymers, P(MeOx-b-BuOx) or P(EtOx-b-BuOx), comprised of 1) hydrophilic 2-methyl-2-
oxazoline (MeOx) or 2-ethyl-2-oxazoline (EtOx) and 2) hydrophobic 2-butyl-2-oxazoline (BuOx)
repeating units. The conjugates contained from 2 to 3 POx chains joining the protein amino groups
via cleavable -(ss)- or non-cleavable –(cc)- linkers at the BuOx block terminus. They retained 30%
to 50% of initial SOD1 activity, were conformationally and thermally stable and assembled in 8 or
20 nm aggregates in aqueous solution. They had little if any toxicity to CATH.a neurons and
displayed enhanced uptake in these neurons as compared to native or PEGylated SOD1. Of the
two conjugates, SOD1-(cc)-P(MeOx-b-BuOx) and SOD1-(cc)-P(EtOx-b-BuOx) compared, the
latter was entering cells 4 to 7 times faster and at 6 h colocalized predominantly with endoplasmic
reticulum (41 ± 3%) and mitochondria (21 ± 2%). Colocalization with endocytosis markers and
pathway inhibition assays suggested that it was internalized through lipid raft/caveolae, also
employed by the P(EtOx-b-BuOx) copolymer. The SOD activity in cell lysates and ability to
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attenuate angiotensin II (Ang II)-induced superoxide in live cells were increased for this conjugate
compared to SOD1 and PEG-SOD1. Studies in mice showed that SOD1-POx had ca. 1.75 times
longer half-life in blood than native SOD1 (28.4 vs 15.9 min) and after i.v. administration
penetrated the BBB significantly faster than albumin to accumulate in brain parenchyma. The
conjugate maintained high stability both in serum and in brain (77% vs. 84% at 1 h post injection).
Its amount taken up by the brain reached a maximum value of 0.08%ID/g (percent of the injected
dose taken up per gram of brain) 4 h post injection. The entry of SOD1-(cc)-P(EtOx-b-BuOx) to
the brain was mediated by a non-saturable mechanism. Altogether, SOD1-POx conjugates are
promising candidates as macromolecular antioxidant therapies for superoxide-associated diseases
such as Ang II induced neuro-cardiovascular diseases.
Keywords
superoxide dismutase 1; polyoxazoline; reactive oxygen species; oxidative stress; neurons; blood
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1. Introduction
Elevation of reactive oxygen species (ROS) levels in the central nervous system (CNS) is
related to multiple severe human diseases such as stroke, neurodegenerative disorders and
neuro-cardiovascular diseases 1-3. Specifically superoxide (O2•-) can cause oxidative
damage to cellular components, induce apoptosis and tissue injury, and participate in redox
signaling pathways leading to detrimental physiological effects. For example, the
endogenous vasoconstrictor peptide angiotensin II (Ang II) induces an increase in
intracellular superoxide in distinct regions of the brain, leading to increased neuronal
activation and sympathoexcitation which play a key role in the pathogenesis of neuro-
cardiovascular diseases such as hypertension and heart failure 1-3. Catalytic or non-catalytic
superoxide scavengers can remove the excess intracellular superoxide, attenuate oxidative
injury and inhibit redox signaling, and thus serve as potential therapeutic antioxidants for
multiple superoxide-related diseases including Ang II-dependent neuro-cardiovascular
diseases 3-7.
The enzyme superoxide dismutase 1 (SOD1, also known as Cu,Zn/SOD) efficiently
catalyzes the dismutation of superoxide into oxygen and hydrogen peroxide. It is a stable
homodimer of identical 16 kDa subunits held together primarily by hydrophobic interactions
and cofactored with copper and zinc 8, 9. SOD1 has high conformational and thermal
stability, and thus has great potential to be developed as a therapeutic agent for superoxide-
related diseases 10. However, like many other therapeutic proteins, SOD1 has a very short
blood circulation time and is incapable of crossing the blood brain barrier (BBB) or neuronal
cell membranes to reach its target sites 11. Conjugation of SOD1 with poly(ethylene glycol)
(PEGylation) significantly increased its retention time in plasma but did not significantly
enhance its cellular delivery and transport across the BBB 12-14. Alternatively, other
conjugation strategies have been developed recently to enhance the cellular or brain delivery
of SOD1, such as conjugation with targeting antibody to endothelial determinants 15-18, cell
penetrating peptide 19 or BBB penetrating nanoparticles 20.
One promising strategy to address this problem is to conjugate SOD1 with amphiphilic
triblock copolymers such as poly(ethylene glycol)-b-poly(propylene glycol)-b-poly(ethylene
glycol) (PEG-PPG-PEG), known as Pluronic® or poloxamer. It has been shown that
conjugation with Pluronics can increase the cellular delivery and BBB permeability of
multiple proteins while also increasing their in vivo stability and blood circulation
time 9, 21-24. We found that SOD1-Pluronic conjugates exhibit significantly enhanced
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neuronal delivery as compared to native SOD1 or PEGylated SOD1 (SOD1-PEG) 9. The
detailed in vivo therapeutic potential of protein-Pluronic conjugates is currently under
investigation in several animal disease models.
Recently, amphiphilic poly(2-oxazoline) (POx) block copolymers were developed as an
alternative to Pluronics for protein modification 25. POx are synthesized by living cationic
ring-opening polymerization (LCROP) of 2-oxazoline monomers. This highly living and
versatile polymerization technique yields well-defined POx with low dispersity and can be
used to produce a variety of structures bearing defined functional end and pendant
groups 25-28. The hydrophilic/hydrophobic balance of POx can be tuned over a broad range
by varying the monomer unit side chains and architecture. This is expected to be critical to
modulate cellular binding of the protein-POx conjugate while maintaining its stability 25, 29.
Notably, POx display greater chemical stability compared to polyethers, such as PEG or
Pluronic, which are prone to oxidative degradation.
In our previous study, a model protein, horseradish peroxidase (HRP), was conjugated with
two block copolymers, one random copolymer and one homopolymer of POx. The block
copolymer based HRP-POx conjugates exhibited significantly enhanced cellular binding and
uptake compared to native HRP or homopolymer-based conjugates 25. In the present study,
we synthesized SOD1-POx conjugates using the same pair of POx block copolymers to
evaluate the impact of the conjugation on brain delivery of SOD1. Moreover, the
amphiphilic POx were conjugated with SOD1 by means of biodegradable and non-
biodegradable linkers. The paper presents new data on 1) synthesis and characterization of
SOD1-POx conjugates by multiple analytical and biophysical techniques; 2) the
cytotoxicity, cellular uptake and intracellular trafficking of SOD1-POx conjugates; 3) the
intracellular activity of a selected SOD1-POx conjugate in CATH.a neuronal cells; and
finally, 4) the pharmacokinetics, brain delivery as well as tissue distribution of SOD1-POx
conjugate in a mouse model.




synthesized under inert conditions by a two-step living cationic polymerization as described
before 25. SOD1 and SOD1-PEG from bovine erythrocytes, N,N-dimethylformamide
(DMF), anhydrous dichloromethane, ethanol, sinapic acid, acetonitrile, trifluoroacetic acid
(TFA), pyrogallol, 2,4,6-trinitrobenzenesulfonic acid (TNBS), N-6,2'-O-dibutyryl adenosine
3',5'-cyclic-monophosphate (AMP), sucrose, methyl-beta-cyclodextrin (MBCD), superoxide
anion assay kit, Ang II, chloramine-T, trichloroacetic acid were purchased from Sigma-
Aldrich Co. (St. Louis, MO). Dithiobis(succinimidyl propionate) (DSP) and di-succinimidyl
propionate (DSS) were from Pierce Biotech Co. (Rockford, IL). Sephadex LH-20 gel and
Illustra NAP-5 columns were from GE Healthcare (Waukesha, WI). Amicon ultra-4
centrifugal filter units, MWCO 10K, 13mm syringe filter (0.22 μm and 0.45 μm), micro
BCA protein assay kit, bovine serum albumin (BSA), 3,3',5,5' tetramethylbenzidine (TMB),
TMB stop solution, NUNC immuno 96-well plate, NUNC LumiNunc 96-well plate and
NUNC Lab-Tek II chambered slide were from Thermo Fisher Scientific (Waltham, MA).
Tris-HCL Precast gels (12%),Biosafe coomassie stain and SYPRO® Ruby stain solution
were from Bio-Rad (Hercules, CA). Primary bovine SOD1 antibody (rabbit IgG) and
secondary HRP-conjugated antibody to rabbit IgG were from Abcam (Cambridge, MA).
Alexa Fluor® 647 protein labeling kit, Hoechst 33342, MitoTracker®, LysoTracker®, ER-
Tracker®, Alexa Fluor® 488-conjugated transferrin (Tf) and cholera toxin B (CTB) were
from Invitrogen (Carlsbad, CA). Methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine (CMH),
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deferoxamine methanesulfonate salt (DF) and diethyldithiocarbamic acid sodium (DETC)
were from Noxygen Science Transfer & Diagnostics GmbH (Elzach, Germany).
2.2. Devices
Size-exclusion chromatography (SEC) was performed on a ÄKTA fast protein liquid
chromatography (ÄKTA FPLC™) system with a Superdex™ 75 column (10 × 300 mm)
from GE Healthcare and a Shimadzu high performance liquid chromatography (HPLC)
system with a TSKgel G2000SWxl column (7.8× 300 mm) from Tosoh Co. (Japan). Matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)
was carried out with a MALDI-TOF-TOF 4800 system (Applied Biosystems, Foster City,
CA) in positive reflector mode. An Aviv circular dichroism (CD) model 202SF spectrometer
(Aviv Biomedical, Inc., Lakewood, NJ) was used for the characterization of secondary
structures of SOD1 and SOD1-POx conjugates. A Microcal VP-DSC differential scanning
calorimeter (Microcal, Northampton, MA) was used for the measurement of protein melting
curves. Particle size and size distribution of protein solutions were determined by dynamic
light scattering (DLS) using Nano series Zetasizer (Malvern Instrument Inc., Westborough,
MA). Confocal microscopy was carried out with a LSM 710 confocal imaging system (Carl
Zeiss, Peabody, MA). Flow cytometry was carried out with a LSR II flow cytometer (BD
Biosciences, San Jose, CA). Electron paramagnetic resonance (EPR) spectroscopy was
performed with a Bruker Biospin e-scan spectrometer (Bruker, Billerica, MA).
2.3. Synthesis and Purification of SOD1-POx
SOD1-POx conjugates were synthesized analog to the procedure described previously 25.
Briefly, secondary amine of the piperazine-terminated POx was reacted with
homofunctional linkers DSS or DSP. 55 mg of POx was reacted with a 20-fold molar excess
of DSS in DMF. The mixture was supplemented with sodium borate buffer (0.1 M, pH 8.0)
and reacted for 30 min at r.t.. The activated POx was purified by gel filtration on a Sephadex
LH-20 column in dry dichloromethane and 15 mg of SOD1 in sodium borate buffer (0.1 M,
pH 8.0) was added. The reaction mixture was incubated overnight at 4 °C. The resulting
SOD1-POx conjugates were purified by FPLC using 0.1 M phosphate buffered saline (PBS,
pH 7.4) as the mobile phase and UV detection at 254 nm. The conjugates were desalted and
lyophilized for further characterization.
2.4. Characterization of SOD1-POx conjugates
2.4.1. Chromatography—Purity and aggregation of SOD1-POx were analyzed by SEC.
The conjugates were analyzed using a mobile phase consisting of methanol (5%) and pH
6.8, 0.1 M NaH2PO4, 0.2 M NaCl buffer (95%) and UV detection at 220 nm.
2.4.2. Mass spectrometry—Molar mass of SOD1-POx was determined by matrix-
assisted laser desorption/ionization time of flight mass spectroscopy (MALDI-ToF MS)
using saturated sinapic acid solution in 50% acetonitrile and 0.1% aqueous TFA as the
matrix. The mass spectrometer was calibrated against insulin (5729.61 Da) and albumin
(66,429.09 Da).
2.4.3. Electrophoresis—Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) analysis was performed as described before 25. The gel was stained by Biosafe
coomassie stain for 1 h and destained in water.
2.4.4. Degree of modification by TNBS assay—The degree of protein modification
was determined by a TNBS assay as described before 25. Briefly, 10 μL of SOD1 or SOD1-
POx solutions (0.1 - 0.6 mg/mL) were mixed with 10 μL of TNBS solution (1.7 mM) in 80
Tong et al. Page 4













μL of sodium borate buffer (0.1 M, pH 9.5) and incubated at 37 °C for 2 h. The absorbance
at 405 nm was measured using a microplate reader (Spectra Max M5, MDS, CA). The
degree of modification (average number of modified amino groups) was calculated
according to:
(1)
where Anative and Amodified are the absorbencies and Cnative and Cmodified are the
concentrations of SOD1 and SOD1-POx respectively. The total number of primary amino
groups including lysine residues and terminal amine group of a SOD1 dimer is 22.
2.4.5. Enzymatic activity by pyrogallol auto-oxidation assay—Pyrogallol auto-
oxidation assay was used to quantify the residual enzymatic activity of SOD1-POx as
described before 9. Briefly, 20 μl of 0.0002-200 μg/mL SOD1 or SOD1-POx was mixed
with 20 μl of freshly prepared pyrogallol solution (0.5 mg/mL) and supplemented with 180
μl Tris-HCl buffer (0.1 M, pH 8) containing 1 mM diethylene triamine pentaacetic acid.
Deionized water (DIH2O) without enzyme and/or without pyrogallol was used as the
control. The reaction mixtures were prepared in triplicate and the rates of autoxidation were
measured immediately by recording the increases of absorbance at 420 nm up to 10 min.
The inhibition rate (%) was calculated by:
(2)
where S1 is the slope for enzyme-free water with pyrogallol, S2 is the slope for enzyme-free
water without pyrogallol, and SS is the slope of the sample with pyrogallol. The half
maximum inhibitory concentration (IC50) and the number of SOD activity unit per 1 mg
protein were calculated. The residual activity of SOD1-POx was expressed as the percentage
of unit number of unmodified SOD1.
2.4.6. Circular dichroism (CD)—SOD1 or SOD1-POx was dissolved in PBS buffer (pH
7.4) at 0.5 mg/mL. CD spectra were recorded between 200 and 260 nm using an Aviv CD
spectrometer with a cuvette of 0.1 cm path length. Spectra were recorded in 1 nm
decrements and the given spectra correspond to the average of three wavelength scans using
the pure solvent as the background. The mean residue molar ellipticity [θ] was calculated
by:
(3)
where θ is the observed ellipticity (deg), M, the mean residue molecular weight (g/mol), C,
the protein concentration (g/mL) and l, the optical path length (cm) 25.
2.4.7. Differential scanning calorimetry (DSC)—Melting curves of SOD1 or SOD1-
POx solution were obtained on a Microcal DSC. SOD1 or SOD1-POx was dissolved in PBS
buffer (pH 7.4) at 2.0 mg/mL. Melting curves were obtained from 10°C to 110°C in 0.2°C
increments. Transition temperatures (Tm) of SOD1 and SOD1-POx at which 50% of the
protein denatured were obtained 30.
2.4.8. Dynamic light scattering (DLS)—Aggregation of SOD1 or SOD1-POx was
analyzed by photon correlation spectroscopy (i.e. DLS) in a thermostatic cell at a scattering
angle of 90°. SOD1 or SOD1-POx was dissolved in PBS buffer (pH 7.4) at 0.5 mg/mL. All
measurements were performed at 25°C. Intensity-based and volume-based size distributions
were generated by the software provided by the manufacturer.
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CATH.a neuronal cells (ATCC CRL-11179™) were seeded in 6-well plates at 500,000
cells/well or in 24-well plates at 150,000 cells/well (for cytotoxicity study) or in 2-well
chambered slides (for confocal microscopy) in RPMI-1640 medium (Invitrogen, Carlsbad,
CA) supplemented with 1% penicillin/streptomycin, 4% fetal bovine serum (Invitrogen,
Carlsbad, CA) and 8% horse serum (Gibco, Life Tech., Grand Island, NY). CATH.a neurons
were differentiated using 1 mM of fresh AMP every 2 days. The cells were typically
cultured for 6-8 days for full expression of Ang II receptors.
2.6. Cytotoxicity assay
Neuronal toxicity of SOD1 and SOD1-POx was determined using a cell counting kit
(Dojindo Molecular Technologies, Inc., Gaithersburg, MD) as described before 9. Briefly,
cells were seeded in 24-well plates and cultured. Culture media was renewed with media
containing 80 μg/mL of SOD1 or SOD1-POx, or 100 μg/mL of PEG5000-b-poly(L-
lysine)50 (PEG-b-PLL) (Alamanda Polymers, Inc. Huntsville, AL) as a positive control.
After that the cells were incubated with SOD1 or SOD1-POx for different periods (1 h-24
h). The media was renewed and the cells were allowed to grow for additional 48 h. The
media was renewed only this time containing 10% CCK-8 solution (2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt). The
absorbance at 450 nm was recorded in a plate reader after 1 h incubation. The cell viability
was calculated by:
(4)
Each treatment was repeated four times and data are presented as means ± SEM.
2.7. Cellular uptake in CATH.a neuronal cells
Cellular uptake of SOD1, SOD1-PEG and SOD1-POx was quantitatively analyzed using
SOD1 ELISA. Briefly, cells were seeded in 24-well plates and cultured until the media was
replaced with fresh serum-free medium containing 80 μg/mL of SOD1, SOD1-PEG or
SOD1-POx. The cells were incubated with SOD1, SOD1-PEG or SOD1-POx for different
time periods (1-24 h). Cells were rinsed twice with PBS, collected and re-suspended. The
cell suspensions were sonicated to prepare cell-free extracts. SOD1 ELISA was performed
according to a protocol described previously, with some modifications 31, 32. Briefly, cell-
free extract containing approx. 50 to 100 μg of cellular proteins were loaded into a NUNC
immuno 96-well plate and immobilized by incubation at 37°C for 2 h. At r.t., the coated
wells were incubated with 1% BSA in PBS for 2 h to block the remaining protein-binding
sites. Next, the wells were incubated with primary bovine SOD1 antibody (1:500 dilution)
for 2 h and then secondary HRP-conjugated antibody (1:120,000 dilution) for 2 h. Finally,
the wells were incubated with TMB solution and supplemented with equal volume of TMB
stop solution. The absorbance at 450 nm was recorded in a plate reader. SOD1, SOD1-PEG
or SOD1-POx at different concentrations was used to construct the calibration curve for
each group. SOD1 concentration was normalized to the cellular protein concentration
determined by MicroBCA assay. Each treatment was repeated three times and data are
presented as means ± SEM.
2.8. Fluorescent labeling, confocal microscopy and flow cytometry
2.8.1. Fluorescent labeling—SOD1 and SOD1-POx were labeled with fluorescent probe
Alexa Fluor® 647 according to a protocol provided by the manufacturer. Briefly, 1 mg of
SOD1 or SOD1-POx was mixed with the amine-reactive dye in sodium bicarbonate buffer
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(0.1 M, pH 8.0). The reaction was allowed to complete at r.t. for 1 h. The labeled protein
was purified by gel filtration and lyophilized. The absorbance at 650 nm of the conjugate
was measured by a plate reader. The degree of labeling (S, mol dye per mol protein) was
calculated by:
(5)
where D is the dilution factor of the conjugate solution, M is the protein concentration and
239,000 is the approx. molar extinction coefficient of the dye at 650 nm. S of both SOD1-
POx conjugates were found to be similar: 0.67 for SOD1-(cc)-P(MeOx-b-BuOx) and 0.64
for SOD1-(cc)-P(EtOx-b-BuOx), and lower than that of SOD1 (S=1.67).
Free P(EtOx-b-BuOx) was also labeled with the same dye using a modified protocol.
Briefly, 4 mg of P(EtOx-b-BuOx) was mixed with the dye in DMF. The reaction mixture
was supplemented with sodium borate buffer (0.1 M, pH 8.0) and reacted at r.t. for 2 h. The
labeled polymer was purified by gel filtration and lyophilized. The absorbance at 650 nm
was measured in a plate reader. The labeling efficiency was estimated to be 20%.
2.8.2. Visualization of cellular uptake by confocal laser scanning microscopy
(CLSM)—The cellular uptake of fluorescently-labeled SOD1 and SOD1-POx was observed
by CLSM. Briefly, cells were seeded in 4-well chambered slide and cultured as described
above until the media was replaced with fresh, serum-free medium containing 80 μg/mL of
fluorescently-labeled SOD1 or SOD1-POx. Cells were incubated with fluorescently-labeled
SOD1 or SOD1-POx for different time period (1 -24 h). The cells were rinsed twice with
PBS and fluorescent images were collected. About 10-15 images containing 100-200 cells
were recorded for each group and each time point, and the fluorescent intensity was
quantified using a public domain imaging processing software (Image J from NIH).
2.8.3 Intracellular localization—The intracellular localization of SOD1-POx was
studied by CLSM. Briefly, cells were cultured as described above and treated with 80 μg/
mL of fluorescently-labeled SOD1-POx for 6 h. Organelles, including nucleus,
mitochondria, lysosome and endoplasmic reticulum (ER) were stained with specific
fluorescent dyes for 30 min before imaging. Then, cells were rinsed twice with PBS and
fluorescent images were taken. About 10-15 images containing 100-200 cells were collected
for each group, and the colocalization ratio of fluorescently-labeled SOD1-POx with each
fluorescent dye was calculated using Image J.
2.8.4. Endocytosis—The endocytosis pathway of SOD1-POx was studied by CLSM and
flow cytometry as described elsewhere 33, 34. 1. Colocalization with specific endocytosis
markers: Tf and CTB were used as the markers of clathrin-mediated endocytosis and lipid
raft/caveolae-mediated endocytosis, respectively. Briefly, cells were cultured as described
above and co-treated with both 80 μg/mL of fluorescently-labeled SOD1-POx and
fluorescently-labeled transferrin or CTB for 6 h. The colocalization ratio of SOD1-POx with
these endocytosis markers was analyzed using Image J. 2. Inhibition of specific endocytosis
pathway: Sucrose and MBCD were used as the specific inhibitors for clathrin-mediated
endocytosis and lipid raft/caveolae-mediated endocytosis, respectively. For CLSM analysis,
cells were cultured as described above. Then the cells were pretreated with 0.4 M of sucrose
or 4 mM of MBCD for 30 min and then co-treated with fluorescently-labeled SOD1-POx for
6 h. The cellular uptake of SOD1-POx was observed by CLSM, quantitatively analyzed
(Image J) and compared with non-inhibited controls. For flow cytometry analysis, cells were
cultured in 24-well plate as described above. The cells were pretreated with 0.4 M of sucrose
or 4 mM of MBCD for 30 min and then co-treated with fluorescently-labeled SOD1-POx for
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6 h. The cellular uptake of SOD1-POx was expressed as the normalized mean fluorescence
of gated cells and compared with non-inhibited controls.
The endocytosis pathway of free P(EtOx-b-BuOx) was also studied by CLSM and flow
cytometry in a similar way as described above. Cells were treated with 50 μg/mL of
fluorescently-labeled P(EtOx-b-BuOx) for 1 h. The colocalization with Tf and CTB, and the
inhibition effects of sucrose and MBCD were analyzed.
2.9. Intracellular SOD activity assay
Intracellular activity of SOD1-POx was quantitatively determined using a luminol-based
superoxide anion assay kit. The oxidation of luminol by superoxide results in the formation
of chemiluminescence light, which can be further amplified by a specific enhancer. Active
SOD can scavenge superoxide and thus inhibit the chemiluminescence signal. After 6-8 days
culture, CATH.a neuronal cells in 6-well plates were incubated with 80 μg/mL of SOD1,
SOD1-PEG or SOD1-POx in fresh, serum-free medium for 12 h. Cells were washed twice
with PBS, collected and resuspended. The cell suspensions were sonicated to prepare cell-
free extracts. The superoxide anion assay was performed according to a protocol provided
by the manufacturer. Briefly, hypoxanthine-xanthine oxidase (HX-XO) catalytic system was
used to generate superoxide. Samples contained xanthine oxidase, xanthine, luminol,
enhancer, and cell-free extract or control. The reaction mixture was loaded into a LumiNunc
96-well plate and the chemiluminescence signal was recorded in a plate reader immediately.
Each treatment was repeated three times and data are presented as means ± SEM.
2.10. Intracellular electron paramagnetic resonance (EPR) spectroscopy
The intracellular superoxide levels in CATH.a neuronal cells were quantitatively measured
by EPR spectroscopy as described before, with some modifications 35. After 6-8 days
culture, CATH.a neuronal cells in 6-well plates were incubated with 80 μg/mL of SOD1,
SOD1-PEG or SOD1-POx in fresh, serum-free medium for 12 h. Cells were washed twice
with EPR buffer (pH 7.4), and incubated with 1mL of EPR buffer containing 200 μM of
CMH, a cell-permeable superoxide-sensitive spin probe for 1 h at 37°C. After incubation,
the cells were stimulated with 100 nM of Ang II for 30 min. After stimulation ca. 0.9 mL of
buffer was aspirated from the well, the cells were collected, resuspended with the remaining
buffer, and cell suspension were loaded into the EPR spectrometer to record the generation
of superoxide for 10 min. To compensate for the difference in cell number between samples,
the EPR amplitude of each sample was normalized to cell number determined by cell
counting. Each treatment was repeated three times and data are presented as means ± SEM.
2.11. Animal studies*
2.11.1. Radioactive labeling (125I-SOD1-POx)—SOD1 or SOD1-POx samples were
radioactively labeled by the chloramine-T method as previously described 36. Briefly, SOD1
or SOD1-POx conjugate was incubated with 0.5 mCi Na125I (Perkin Elmer Life Sciences,
Boston, MA) and 10 μg of chloramine-T freshly made for 60 sec. The mixture was purified
by Illustra NAP-5 columns. Fractions were collected in Eppendorf tubes that were pre-
coated with 50 μL of 1% BSA in lactated Ringer's solution (LR-BSA) to prevent non-
specific absorbance. The radioactivities of fractions were counted in a PerkinElmer γ-
counter and trichloroacetic acid (TCA) precipitation was conducted to determine the iodine
association of labeled samples. Fractions containing more than 100,000 cpm/μL and in
which the iodine association by TCA precipitation was more than 90% were used for the
*Animal study was carried out and data were analyzed by X.Y. as a visiting scholar at the University of Washington (in W. A.B.'s
lab).
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animal study. Similarly, BSA was labeled with Na131I (Perkin Elmer Life Sciences, Boston,
MA) by chloramine-T method. Furthermore, electrophoresis was performed to confirm the
iodination. Non-radioactively labeled samples or radioactively labeled samples containing
50,000 cpm were subjected to electrophoresis under non-reducing denaturing conditions.
After fixing, the gel of non-radioactive labeled samples was stained in SYPRO® Ruby
solution; whereas gel of radioactive labeled samples was dried and exposed to Blue Basic
Autorad Film (Bioexpress, Kaysville, UT) overnight.
2.11.2. Animal procedures—Pharmacokinetics (PK) and biodistribution studies were
conducted with CD-1 male mice (8 to 10 weeks of age, Charles River Laboratories, Inc.
Wilmington, MA). All experiments were conducted after institutional approval of the animal
use subcommittee of the Veterans Affairs Puget Sound Health Care System, which
subscribes to the National Institutes of Health Guide for Care and Use of Laboratory
Animals. Mice were anesthetized by i.p. injection of urethane (40%). Radiolabeled sample
was prepared and injected into the jugular vein. Blood from the carotid artery was collected
at various time points. Mice were immediately decapitated and the whole brain and/or other
tissues removed and weighed. The arterial blood was centrifuged and the serum was
collected. The radioactivity of tissue and serum samples were counted in a γ-counter. In
some cases, a brain washout was performed before decapitating and the brain was collected.
Briefly, after opening the abdomen, arterial blood was collected from the abdominal aorta.
The thorax was then opened to expose the heart. The descending aorta was clamped, both
jugular veins severed, and LR-BSA was perfused over 1 min into the left ventricle of the
heart. Finally, the mouse was decapitated and the whole brain removed and weighed for
further experiments.
2.11. 3. Serum clearance and influx rate across the blood-brain barrier (BBB)
—Mice anesthetized with urethane received an i.v. injection of 125I-SOD1 or 125I-SOD1-
POx with 131I-albumin (300,000 cpm of each) into the jugular vein. Blood from the carotid
artery and brain was collected at various time points between 2 and 240 min after injection.
The radioactivities of brain and serum samples were counted in a γ-counter. The percent of
the i.v. injected dose ID/ μL in serum (%ID/μL) and the dose taken up per gram of brain at
time t (%ID/g brain) were by:
(6)
(7)
Where ID is the cpm i.v. injected. Am and Cp(t) are the cpm/g of brain and the cpm/μL of
serum at time t, respectively.
The serum concentration (percent of the i.v. injected dose ID/ μL in serum, %ID/μL) was
plotted against time to describe the serum clearance. The slope between log(%ID/μL) and
time was used to calculate the half time clearance from blood. Multiple-time regression
analysis was applied to calculate the blood-to-brain unidirectional influx rate (Ki) of the
radiolabeled compounds into the brain. The brain/serum ratios (μL/g) were plotted against
exposure time estimated from:
(8)
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Where Am and Cp(t) are the cpm/g of brain and the cpm/μL of serum at time t, respectively.
Ki was measured as the slope for the linear portion of the relation between brain/serum
ratios and respective exposure times 37, 38. The exposure time was calculated as the area
under the serum concentration time curve (integral part of Eq.8) divided by serum
concentration at time t. The y-intercept of the line represents Vi (0), the distribution volume
in the brain at t=0.
2.11. 4. Inhibition study—To determine whether brain uptake of 125I-SOD1-POx was
saturable, an excess amount of non-radiolabeled SOD1-POx was co-injected with
radiolabeled samples into the jugular vein. Blood and brain were collected at 60 min after
i.v. injection as described previously and processed. Results were interpreted as brain/serum
ratios.
2.11.5. Enzymatic stability—To determine the presence of intact 125I-SOD1-POx in
serum and brain, samples were collected at 15, 60, and 240 min post-i.v. and immediately
used for TCA precipitation. Thereafter, the mouse was decapitated and the whole brain was
removed, weighed, and placed in an ice-cold glass homogenizer. The brain was
homogenized (10 strokes) in sodium phosphate buffer and then centrifuged at 5400 g for 10
min. Brain supernatant was transferred to a new tube and mixed with an equal amount of
30% TCA. To correct for ex vivo degradation, processing control samples were prepared by
adding 10,000 cpm of 125I-SOD1-POx into serum or brains obtained from mice that had
received no i.v. injection of radioactive material and processed similarly. All the TCA
precipitated samples were then centrifuged at 5400 g for another 10 min and the supernatant
and pellet were collected for radioactivity measurement. The stability was estimated by the
percentage of radioactivity present in the pellet divided by the total radioactivity in both of
the pellet and the supernatant and then normalized by the percent of processing control. In
some cases, a brain washout was performed prior brain collection as described previously.
2.11.6. Capillary depletion—Brain washout was performed at 60 min after i.v. injection
of 125I-SOD1-POx. This procedure removed the radioactively labeled material in the
vascular space and loosely adhering to the luminal side of brain capillaries. Thereafter, the
mouse was decapitated and the whole brain was removed, weighed, and homogenized (10
strokes) in physiological buffer (10 mM HEPES, 141 mM NaCL, 4 mM KCl, 2.8 mM
CaCl2, 1 mM MgSO4, 1 mM NaH2PO4, and 10 mM D-glucose, pH 7.4). Dextran solution
was added to the homogenate, mixed, and homogenized a second time (3 strokes). The
homogenate was centrifuged at 5400 g for 15 min at 40°C. The resulting supernatant (brain
parenchyma fraction) and pellet (capillary fraction) were separated and the level of
radioactivity for each fraction was determined using a γ counter. The parenchyma/serum
and capillary/serum ratios (μL/g) were calculated as: (cpm/g of tissue) /(cpm/μL of serum).
2.11.7. Tissue distribution—Mice anesthetized by with urethane received an i.v.
injection of 0.2 mL of LR-BSA containing both 131I-SOD1 and 125I-SOD1-POx (300,000
cpm of each) into the jugular vein. In a separate group, 131I-albumin (300,000 cpm) was i.v.
injected similarly. Blood from the carotid artery was collected at 60 min after injection and
mice were immediately decapitated and brain, heart, liver, spleen, kidney, lung, stomach and
tight muscle were removed and weighted. The arterial blood was centrifuged at 5400 g for
10 min and the serum was collected. The radioactivity of tissue and serum samples were
counted using a γ-counter. The tissue/serum ratios of 131I-SOD1 and 125I-SOD1-POx in
each tissue were statistically compared (paried t-test, n=5).
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Statistical analysis was done using student's t-test for two groups and one-way ANOVA for
multiple groups followed by Newman-Keuls multiple comparison test or by a 2-tailed
unpaired t test with Welch's correction. A minimum p value of 0.05 was estimated as the
significance level. Statistic analysis was done with the Prism 5.0 software (GraphPad, San
Diego, CA, USA).
3. Results
3.1. Synthesis and characterization of SOD1-POx
Two well-defined block copolymers, P(MeOx-b-BuOx) and P(EtOx-b-BuOx) (Figure 1 and
Table 1) were conjugated via the secondary amine function of the piperazine terminus of the
polymers with SOD1 following a method we described previously. The synthesis for POx
and SOD1-POx conjugates is outlined in Scheme 1. First, the polymers were reacted with
bifunctional linkers DSS or DSP to produce N-hydroxysuccinimide terminated derivatives.
Second, these activated polymers were reacted with SOD1 in an aqueous buffer (pH 8.0). To
minimize the loss of SOD1 activity no organic solvent was added during this second step.
The reactions proceeded readily and generated SOD1-POx conjugates with either a stable
linker or degradable linker, which are denoted below as “-(cc)-“ and “-(ss)-“, respectively.
Table 2 summarizes the abbreviated names of the conjugates along with their molecular
characteristics and catalytic activity. The conjugates were purified by FPLC to remove non-
modified proteins and excess of polymer. The yield of the POx-SOD1 conjugation varied
slightly from 30 to 50% as per initial SOD1.
The SOD1-POx conjugates were analyzed by SEC, MALDI-ToF MS and SDS-PAGE. The
conjugates eluted in a broad peak with a maximum having a shorter elution time around 7.5
min as compared to 8.1 min for the native SOD1 (Figure S1 in supplemental data). The
main peak also contained a more rapidly eluting “shoulder” around 6 - 6.5 min, which can
be ascribed to highly modified protein fractions. In addition, a minor faction (ca. 3 to 5% of
the total protein) rapidly eluting at 5.5 min was found in all conjugate samples, probably due
to aggregation of highly modified protein. The MALDI-ToF mass spectra (Figure 2)
suggests that while the native SOD1 contained a mixture of a protein monomer (16 kDa) and
a dimer (32 kDa), the SOD1-POx conjugates represented mainly a dimer with one (39 to 40
kDa) or two (46-48 kDa) polymer chains attached. In addition the conjugate samples also
contained some unmodified SOD1 monomer and dimer, which probably originated from the
native enzyme not participating in the reaction or from degradation during sampling. It
should be pointed out that MALDI-ToF-MS may not detect the highly-modified protein
conjugates due to the mass bias of the method, which can be still present in the mixture
similar to PEGylated SOD1 39. Such highly modified conjugates appeared in the SDS-
PAGE, which revealed the existence of multiple protein forms in all SOD1-POx samples,
including a major band of a modified dimer and several smaller bands of higher molar mass
(Figure 3). The latter bands may contain SOD1 with multiple polymer chains attached. This
assumption is corroborated by the mean modification degree of the conjugates determined
by TNBS amino group titration assay (Table 2). Here, the degree of modification varied
from ca. 2.2 for SOD1-(cc)-P(MeOx-b-BuOx) to 3.5 for SOD1-(ss)-P(MeOx-b-BuOx) per
SOD1 dimer. The residual enzymatic activities of SOD1-POx conjugates as determined by
the pyrogallol auto-oxidation assay were found to be around 30% for SOD1-(ss)-P(EtOx-b-
BuOx) and 47% for SOD1-(ss)-P(MeOx-b-BuOx) as compared to native SOD1 (Table 2).
Others reported a similar activity loss (down to ca. 50%) for PEGylated SOD1 40. It was
consistent with previous findings that modification of SOD1 lysines, such as acylation and
carbamoylation, decreases electrostatic attraction of the superoxide anion to the enzyme
active site 11, 41. As SOD1-(cc)-POx and SOD1-(ss)-POx are very similar in terms of their
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degree of modification as well as their residual activities, we selected both SOD1-(cc)-
P(MeOx-b-BuOx) and SOD1-(cc)-P(EtOx-b-BuOx) for further studies.
3.2. Protein stability and aggregation of SOD1-POx
The impact of POx conjugation (POxylation) on the stability of SOD1 was investigated by
circular dicroism (CD) and differential scanning calorimetry (DSC). The CD signals of
SOD1-POx conjugates in the far-UV are practically identical to those for native SOD1,
suggesting that the secondary structure of the protein remained unaffected by the POxylation
(Figure 4). Native SOD1 and SOD1-POx conjugates displayed a single endothermal peak in
the DSC melting curves (Figure S2) and the Tm values of SOD1-POx conjugates were
decreased by only ca. 3.5 °C as compared to the native protein (Tm = 92.1°C) (Table 2).
Thus, the SOD1-POx conjugates and unmodified enzyme have a similar thermal stability.
The aggregation of SOD1-POx conjugates in buffer solution was analyzed by DLS. Using
the volume-based size distributions, some increases in the particle effective diameters were
observed for both SOD1-POx conjugates as compared to the native SOD1 (ca. 5 nm)
(Figure 5). Interestingly, the SOD1-(cc)-P(EtOx-b-BuOx) conjugate, formed larger
aggregates (ca. 20 nm) than SOD1-(cc)-P(MeOx-b-BuOx) (ca. 8 nm). This can be attributed
to the slightly amphiphilic nature of the still water soluble EtOx-block 42, 43. All studied
solutions including native SOD1 contained minor amounts of larger aggregates, which were
more evident in the analysis of the intensity-based size distributions (Figure S3).
3.3. Neuronal cell toxicity and trafficking of SOD1-POx
The cellular interactions of SOD1-POx conjugates were studied using CATH.a neurons as
an in vitro model of neuronal cells. The unmodified SOD1 and SOD1-PEG conjugate were
used for comparison. The exposure of cells to 80 μg/mL of native or POxylated SOD1 for 1
to 24 h did not result in a considerable cytotoxic effect (Figure 6), whereas the exposure to
100 μg/mL of cationic PEG-b-PLL used herein as a positive control generated a significant
time-dependent cytotoxicity. The uptake of SOD1, SOD1-PEG and SOD1-POx in the
CATH.a neurons was analyzed at different time points by measuring the SOD1
concentration in the cell lysates using ELISA. Neither unmodified SOD1 nor SOD1-PEG
exhibited any uptake for up to 24 h within the detection limit of the method (ca. 0.5 ng/mL,
which allows to detect 0.2 ng SOD1/mg of the cellular protein). In contrast, both SOD1-POx
conjugates were readily taken up by the cells in a time-dependent manner during 24 h
(Figure 7a). Interestingly, the SOD1-(cc)-P(EtOx-b-BuOx) conjugate showed 4- to 7-fold
higher uptake rate and levels as compared to the SOD1-(cc)-P(MeOx-b-BuOx) conjugate.
The cellular uptake of SOD1-(cc)-P(EtOx-b-BuOx) during the first 6 h reached as much as
30 ng/mg cell protein. The ELISA data were further corroborated by a CLSM study using
Alexa Fluor® 647 labeled SOD1 and SOD1-POx conjugates. This study confirmed a
considerable increase in the internalization rate of the conjugates as compared to the native
enzyme as well as a clear intracellular localization of the conjugates in CATH.a cells
(Figure 7b). Notably, CLSM revealed a similar trend in the uptake of the SOD1-(cc)-
P(EtOx-b-BuOx) and SOD1-(cc)-P(MeOx-b-BuOx) conjugates suggesting that a slightly
more hydrophobic EtOx-block enhances the internalization of the POxylated SOD1 in the
cells (supplemental Figure S4). Based on the ELISA and CLSM cellular uptake data we
selected SOD1-(cc)-P(EtOx-b-BuOx) as the lead compound for the further studies.
First, the sub-cellular distribution of the SOD1-(cc)-P(EtOx-b-BuOx) conjugate was
examined. Using organelle-specific fluorescent dyes we observed different extents of
colocalization of this conjugate with the nucleus, lysosomes, mitochondria and ER (Figure
8a). As indicated from quantitative analysis of the colocalization data after 6 h incubation
with SOD1-(cc)-P(EtOx-b-BuOx), the conjugate was mainly observed in the ER (41 ±
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3.2%) and mitochondria (21 ± 1.6%) (Figure 8b). The fractions found in the lysosomes (10
± 1.7%) and the nucleus (5.6 ± 0.31%) were considerably smaller.
Secondly, the cell entry mechanism of SOD1-(cc)-P(EtOx-b-BuOx) conjugate was
examined by inhibition of the clathrin-mediated endocytosis (CME) and the lipid raft/
caveolae-mediated endocytosis pathways. The hypertonic sucrose and MBCD are the
commonly-used chemical inhibitors for these pathways 34. We have shown that in our cell
model, these inhibitors indeed decreased the internalization of the protein markers for the
respective pathways – Tf for clathrin and CTB for caveolae (Figure S5). Interestingly, after
co-exposure of the CATH.a cells to each of these markers with the SOD1-(cc)-P(EtOx-b-
BuOx) conjugate, colocalization of the conjugate with CTB (25 ± 2.3%) was found to be
significantly higher than its colocalization with Tf (9.3 ± 0.40%) (Figure 8c and 8d).
Furthermore, the uptake of the conjugate was inhibited significantly by MBCD (p<0.01) but
not by hypertonic sucrose, suggesting that the conjugate is internalized through lipid raft/
caveolae rather than CME (Figure 8e and S6). A very similar colocalization and inhibition
patterns were also observed for the P(EtOx-b-BuOx) block copolymer alone (Figure S7 and
S8), suggesting that the SOD1-POx conjugate may follow the trafficking itinerary of POx
used for the conjugation.
3.4. Intracellular superoxide scavenging by SOD1-POx
The activity of SOD1-(cc)-P(EtOx-b-BuOx) after cell uptake was quantified by the luminol-
based chemiluminescence assay (Figure 9). This assay employs the superoxide-generation
system, HX-XO and luminol, which reacts with the superoxide and emits a strong
chemiluminescence signal. This signal can be completely abolished by depleting the
superoxide with 4 kU/mL of SOD1 or partially abolished with 0.4 kU/mL of SOD1,
indicating that the detected signal is superoxide-dependent (Figure S9). The cell lysate
(blank control) was shown to significantly decrease the chemiluminescence signal compared
to the control. This is likely to be due to the presence of endogenous superoxide dismutases
and other superoxide scavengers in CATH.a cells (Figure 9a). The scavenger activity in
these cells was considerably increased after their treatment with SOD1-(cc)-P(EtOx-b-
BuOx), which was consistent with the accumulation of the active enzyme in the cell lysates.
In contrast, the scavenging activity did not change significantly after the treatment of the
cells with native SOD1 or PEGylated SOD1. A time lapse experiment clearly showed that
the significant reduction in superoxide after treatment with SOD1-(cc)-P(EtOx-b-BuOx)
translates into a much smaller area under the curve for the superoxide concentration (Figure
9b).
Finally, the ability of SOD1, SOD1-PEG and SOD1-(cc)-P(EtOx-b-BuOx) to attenuate the
Ang II-induced increase in intracellular superoxide levels in CATH.a cells was determined
by EPR spectroscopy (Figure 10). A 30 min Ang II stimulation increased the superoxide
levels as determined by an increase in the EPR spectra amplitude. A pretreatment of neurons
with SOD1-(cc)-P(EtOx-b-BuOx) resulted in a decrease of this signal (Figure 10b),
suggesting that this conjugate mitigated the Ang II-induced increase in superoxide level. As
expected, the treatment of the cells with native SOD1 failed to attenuate the response to Ang
II stimulation. PEGylated SOD1 had some anti-oxidant activity as judged by the decreased
EPR signal albeit it was significantly less than the effect observed for POxylated SOD1.
Altogether, the POxylation of SOD1 results in an enhanced transport of the enzyme into
CATH.a neuronal cells and allows significant scavenge of intracellular superoxide generated
in response to Ang II stimulation.
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3.5. Pharmacokinetics, brain uptake and tissue distribution of 125I-SOD1-POx
The animal studies were conducted with a radiolabeled SOD1-(cc)-P(EtOx-b-BuOx)
conjugate prepared by the chloramine-T method (Scheme 1). To confirm the successful
iodination, we analyzed radioactively labeled POxylated SOD1 by autoradiograph gel
(Figure S10). At the electrophoresis conditions, SOD1 presented as a mixture of dimer and
monomer (Lane A). 125I-SOD1-POx showed a similar pattern (Lane B and C), confirming
that the conjugate retained its structure after iodination and the samples injected into animals
for PK studies were of the same composition as those used in nonradioactive experiments.
In Figure 11a the serum concentrations of 125I-SOD1 or 125I-SOD1-(cc)-P(EtOx-b-BuOx)
are plotted against time and compared to co-injected 131I-albumin. The initial volume
distribution (Vt(0)) for 131I albumin was 1.95±0.02 mL (SOD1-POx group) or 2.12±0.03 mL
(SOD1 group). The elimination half-time of 131I albumin was determined to be 3.87 h
(SOD1-POx group) or 3.50 h (SOD1 group) which is consistent with the results previously
found 44, 45, and suggests that we have successfully estimated the pharmacokinetic profiles
of 125I labeled sample and 131I-albumin in these animals. Both samples showed biphasic
clearance from serum (Figure 11a); during the initial phase (0-60 min) (Figure 11b), the
calculated half-time disappearance of SOD1-POx was about 2 times longer as compared to
the native protein (28.4 vs 15.9 min). The initial volume of distributions of SOD1-POx and
SOD1 in blood were 1.47±0.03 mL and 1.78±0.03 mL, respectively.
In Figure 12 a and b, the brain/serum ratio of labeled native and POxylated SOD1,
corrected by the brain/serum ratio for the co-injected 131I-albumin, is plotted against
exposure time to calculate the blood-to-brain influx rate (This allows us to correct results for
each animal for its vascular space and thus more accurately estimate the results). The slope,
Ki, of the linear portion (0-60 min) of the albumin-corrected plot, was 0.052 ±0.006 μL/
g·min (r = 0.86, p <0.0001; n =1-2 mice/time point) for 125I-SOD1-POx, demonstrating that
the substance crossed the BBB significantly faster than albumin. In comparison, no
correlation was observed for 125I-SOD1 that does not cross the BBB any better than
albumin. The initial volume of distribution in brain for SOD1-POx was 2.12±0.05 μL/g. By
4 h post-i.v. injection, the amount of 125I-SOD1-POx taken up by the brain reached a
maximum value of 0.08%ID/g (Figure 12c). Notably, the brain uptake of SOD1-POx was
not saturable, as the brain/serum ratio of 125I-SOD1-POx was not inhibited by an excess
amount of co-injected non-radioactive SOD1-POx (Figure 12d).
The in vivo stability of 125I-SOD1-POx in serum and brain was measured by TCA
precipitation (Table S1). Following i.v. injection, the intact 125I-SOD1-POx present in
serum was determined to be about 104% at 15 min, 99% after 1 h and 77% at 240 min;
whereas in brain the intact 125I-SOD1-POx was about 97% at 15 min, 84% at 60 min and
44% after 240 min. More than 50% of intact 125I-SOD1-POx was observed in the brain for
animals receiving brain washout at 1 h post-i.v. injection. These results indicate that SOD1-
POx is stable in serum and brain for over 1 h after i.v. administration.
To determine whether 125I-SOD1-POx was sequestered by brain endothelial cells or entered
into the brain parenchyma space, capillary depletion with brain washout was performed in
mice 1 h after i.v. injection. As shown in Figure 12e, the brain parenchyma/serum ratio was
found to be significantly higher as compared to the capillary/serum ratio (5.56 ± 0.97 μL/g,
vs 2.78 ±0.40 μL/g, p < 0.05; n =3 mice). This indicates that SOD1-POx can cross the BBB
completely and enter the brain's parenchyma space.
The tissue/serum ratios of 125I-SOD1-POx accumulation in peripheral tissues (heart, liver,
spleen, kidney, lung, muscle and stomach) at 60 min after i.v. injection were determind
(Figure 13). 131I-SOD1 was co-injected and used as control. The tissue/serum ratio of
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SOD1-POx in brain, heart, liver, spleen and lung were all significantly higher than that of
SOD1 (p<0.05, n=5), whereas in kidney, muscle and stomach no significant difference could
be observed.
4. Discussion
In the present study, we successfully modified SOD1 with two amphiphilic POx block
copolymers and evaluated the cellular uptake and therapeutic potential of these conjugates.
These SOD1-POx conjugates were synthesized by a two-step conjugation method. In order
to avoid protein denaturation and to preserve a higher residual enzymatic activity the
conjugation was performed in aqueous media with no added organic cosolvents 46. The
recovered yields (30-50% as per initial amount of SOD1) are comparable to those reported
before for the preparation of HRP-POx conjugates (20-40%) 25. The POxylated SOD1 could
be readily purified and its analysis by SEC, MALDI-ToF MS, SDS-PAGE and TNBS assay
showed that the conjugates contained of 2-3 POx chains per protein dimer. The secondary
structure of SOD1 was preserved as revealed by CD spectroscopy, and no significant SOD1
dimer dissociation was observed. DSC analysis showed that POxylation of SOD1 did not
result in a destabilization of the enzyme. These results indicated that SOD1-POx conjugates
maintained high conformational and thermal stability, which is crucial for future
manufacturing and clinical applications. However, we observed a catalytic activity loss with
a residual activity of 30-40% similar to SOD1-Pluronic conjugates prepared in the same
way 9. This suggests that the lysine modification, rather than conformational changes or
dimer dissociation of SOD1 is accountable for the activity loss of the enzyme.
Consequently, the loss of the enzyme activity is proportional to the degree of modification
and is adjustable by altering the conjugation conditions. For example, the heavily-modified
SOD1-POx conjugates with an average of 5 to 6 conjugated polymers exhibited only 5% of
its original activity (data not shown). Interestingly, when using PMeOx and PEtOx
homopolymers for enzyme modification, the former exhibited a higher influence on the
residual enzymatic activity as compared to the latter 47, 48. Here, we observed a contrary
trend. The conjugates prepared in the present study were moderately modified, bearing in
average 2-3 polymers per enzyme and retained a relatively high residual activity.
Aggregation is a major issue for the development of therapeutic proteins. It is reported that
chemical degradation or modification can induce partial protein unfolding and irreversible
protein aggregation 49, 50. The aggregation behavior of POxylated SOD1-POx as studied by
DLS showed, in both intensity-based and volume-based size distributions, a significant
increase of the hydrodynamic size of aggregates as compared to the native SOD1. SEC
profiles indicated that a small fraction (3-5%) of large size aggregates are formed. The
increased aggregation of SOD1-POx is probably due to the self-association of hydrophobic
blocks (BuOx) of POx exposed on the surface of proteins and thus is likely to be reversible.
It did not result in protein unfolding and conformation change, as no enzyme denaturation
could be detected. However, its effect on the long-term physical and chemical stability of
SOD1 is unclear and calls for further investigations.
The motivation for POxylation of hydrophilic proteins is to enhance the cellular binding and
uptake of the protein 29. In the present study we evaluated the cellular delivery of POxylated
SOD1 in CATH.a neuron cells. SOD1-POx conjugates did not generate a detectable
neuronal toxicity at the concentration of 80 μg/mL. Enhanced neuronal uptake of SOD1-
POx was found by both SOD1 ELISA and fluorescent quantification. Interestingly, SOD1-
P(EtOx-b-BuOx) exhibited a much better cell-uptake as compared to SOD1-P(MeOx-b-
BuOx), whereas in our previous study, HRP-P(MeOx-b-BuOx) showed higher uptake than
that of HRP-P(EtOx-b-BuOx) in both MDCK and Caco-2 cells 25. The variance in the
modification degree and/or formation of different aggregates for both systems is probably
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one reason for the different behavior of the two POxylated proteins. Moreover, HRP-
P(MeOx-b-BuOx) had a higher modification degree than that of SOD1-P(EtOx-b-BuOx)
(1.62 vs. 1.04), but for SOD1 modification, the modification degree of SOD1-P(EtOx-b-
BuOx) in the cellular uptake study was higher (2.18 vs. 2.49). For both conjugates, the
neuronal uptake was slow and time-dependent. For SOD1-P(EtOx-b-BuOx), significant
neuronal internalization was observed after 3 to 6 h treatment, as revealed by CLSM.
Previous studies have demonstrated that modification with amphiphilic block copolymers
such as Pluronics and POx can enhance the cellular uptake of various proteins, however,
little is known about their intracellular fate. We analyzed the intracellular distribution and
endocytosis pathway of SOD1-P(EtOx-b-BuOx) in CATH.a neurons. Our data suggested
that SOD1-P(EtOx-b-BuOx) mainly utilizes lipid raft/caveolae-mediated endocytosis to
internalize into CATH.a neurons which is similar to the internalization of the polymer alone.
SOD1-P(EtOx-b-BuOx) may also utilize caveolae and clathrin-independent pathways,
which also require lipid raft compositions and can be inhibited by cholesterol depletors such
as MBCD 33, 51, 52.
Colocalization studies indicate that SOD1-P(EtOx-b-BuOx) is not entrapped in lysosomes
but accumulates in the ER and to a lesser extent in mitochondria after cell entry. This result
corroborates that SOD1-POx used clathrin-independent endocytosis pathways as these
pathways often do not involve lysosome trafficking 33, 51. It also suggests that SOD1-POx
conjugates should maintain high intracellular activity because they are not trapped and
degraded in lysosomes. Interestingly, high colocalization with mitochondria was observed
(c.a. 18% after 6 h treatment), suggesting that SOD1-P(EtOx-b-BuOx) can be transported to
mitochondria after endocytosis and thus is able to scavenge the intercellular superoxide
generated in this organelle, which is one of the major sources of intracellular ROS 53.
Chemiluminescence assay also confirmed that internalized SOD1-POx were catalytically
active even after 12 h.
Ang II stimulation can induce an increase of intraneuronal superoxide level produced by
NADPH oxidases and/or mitochondria 7. Our previous study showed the SOD1-Pluronic
conjugates can significantly attenuate the increase of superoxide in CATH.a neurons
stimulated by Ang II 9. In the present study, we demonstrated that SOD1-POx displayed the
same capability by using EPR spectroscopy, which is widely accepted for intracellular free
radical measurement 54. The superoxide scavenging ability of SOD1-POx is clearly superior
to native SOD1 and SOD1-PEG, which showed minimal uptake in CATH.a neurons. The
high colocalization of SOD1-POx with mitochondria further reinforced its superoxide
scavenging ability because Ang II stimulates the increase of superoxide in both cytoplasm
and mitochondria. Our data indicates that SOD1-POx are promising candidates as efficient
superoxide scavengers in neuronal cells. However, it should be noted that SOD1-POx alone
is not sufficient to remove intracellular oxidative stress as it generates another type of ROS,
hydrogen peroxide. A combination of SOD1-POx and a hydrogen peroxide scavenger (e.g.
Catalase-POx conjugate) might be a promising strategy to address this problem as indeed
such combination systems have been successfully designed and reported recently 55, 56.
The half-life of SOD1-(cc)-P(EtOx-b-BuOx) in blood is about 1.75 times longer than that of
native SOD1 (28 min vs. 16 min), suggesting a slower elimination and increased circulation
stability of this conjugate. However, this effect is not comparable to PEGylated SOD1,
which results in a half-life of SOD1 of several to 24 h. The high accumulation of SOD1-POx
in brain and other peripheral organs such as liver, spleen and lung may be responsible for the
observed shorter circulation time. Importantly, our data clearly showed that SOD1-POx is
capable of crossing the intact BBB (entry rate of 0.052 ±0.006 μL/g·min) and accumulating
in both brain capillary and parenchyma (67% in parenchyma vs. 33% in brain capillary),
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whereas according to our and previous studies, neither native nor PEGylated SOD1 can
reach the brain. This result is important as it indicates a direct therapeutic potential of
POxylated SOD1 or other proteins for multiple CNS diseases with an intact BBB. Notably,
even though SOD1-POx had relatively short half-life, its portions retained in serum and in
brain still maintained high structural stability (77% vs. 84% at 1 h), indicating that SOD1-
POx is not chemically degraded before or after crossing the BBB and thus most likely
remains active when it reaches the target cells. The BBB transport of SOD1-POx was not
inhibited by an excess of non-radioactively labeled conjugates, indicating that this transport
employed a non-saturable mechanism. The exact mechanism for the entry of SOD1-POx to
the brain is unclear and needs further investigation, but it can be speculated that similar to
the observed endocytosis of SOD1-POx in CATH.a neurons, non-specific transcytosis may
play a role. As the synthesis of POx by living ionic polymerization allows a fine-tuning of
the hydrophilic/lipophilic balance as well as the overall polymer architecture, optimization
of the blood pool residence and trans-BBB transport might be possible. To address both
possibly opposing properties, a better structure-property relationship for the POx as well as
the protein-POx conjugates is needed. Related studies are currently in progress in our
laboratories.
5. Conclusion
In the present study, a new type of SOD1-POx conjugate was synthesized, characterized and
evaluated in vitro and in vivo. SOD1-POx conjugates displayed low to none cytotoxicity and
significantly enhanced neuronal uptake as compared to the native and PEGylated enzyme.
The conjugate utilized caveolae-mediated and/or clathrin and caveolae-independent
endocytosis pathways, rather than the clathrin medidated endocytosis to internalize into
CATH.a neurons. The SOD1-POx maintained its catalytic activity after internalization.
SOD1-POx significantly attenuated the increase of intracellular superoxide stimulated by
Ang II. SOD1-POx showed two-time longer half-life in blood as compared to the native
enzyme. Most importantly, SOD1-POx was able to cross the blood-brain barrier. Our results
indicate that SOD1-POx conjugates might be promising polymer agents for antioxidant
therapies of superoxide-related diseases in brain.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This study was supported by the United States National Institute of Health RO1 grant NS051334, the United States
Department of Defense (DoD) USAMRMC 06108004 and by the Nanomaterials Core Facility of the Nebraska
Center of Nanomedicine supported by NIH COBRE grant RR021937 (all awarded to A.V.K.). R.L. is also thankful
to the King Abdullah University of Science and Technology (KAUST Award No. KUK-F1-029-32, partial salary
support for R.L.). Likewise J.T. has been in part supported by the Program of Excellence Graduate Assistantship
from UNMC. We also gratefully acknowledge Professor Luis Marky (College of Pharmacy, UNMC) for kind
assistance in CD and DSC experiments, Daria Filonova (College of Pharmacy, UNC-Chapel Hill) for her assistance
in preparation of the Table of Contents Graphic, and the assistances of UNMC CLSM, Cell Analysis and MS core
facilities.
References
1. Behl C, Moosmann B. Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as
neuroprotective compounds. Biol Chem. 2002; 383:521–536. [PubMed: 12033440]
2. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992; 59:1609–
1623. [PubMed: 1402908]
Tong et al. Page 17













3. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J
Hypertens. 2000; 18:655–673. [PubMed: 10872549]
4. Zimmerman MC, Davisson RL. Redox signaling in central neural regulation of cardiovascular
function. Prog Biophys Mol Biol. 2004; 84:125–149. [PubMed: 14769433]
5. Welch WJ. Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction.
Hypertension. 2008; 52:51–56. [PubMed: 18474831]
6. Zimmerman MC, Sharma RV, Davisson RL. Superoxide mediates angiotensin II-induced influx of
extracellular calcium in neural cells. Hypertension. 2005; 45:717–723. [PubMed: 15699459]
7. Yin JX, Yang RF, Li S, Renshaw AO, Li YL, Schultz HD, Zimmerman MC. Mitochondria-
produced superoxide mediates angiotensin II-induced inhibition of neuronal potassium current. Am
J Physiol Cell Physiol. 2010; 298:C857–865. [PubMed: 20089930]
8. Rosenbaugh EG, Roat JW, Gao L, Yang RF, Manickam DS, Yin JX, Schultz HD, Bronich TK,
Batrakova EV, Kabanov AV, Zucker IH, Zimmerman MC. The attenuation of central angiotensin
II-dependent pressor response and intra-neuronal signaling by intracarotid injection of
nanoformulated copper/zinc superoxide dismutase. Biomaterials. 2010; 31:5218–5226. [PubMed:
20378166]
9. Yi X, Zimmerman MC, Yang R, Tong J, Vinogradov S, Kabanov AV. Pluronic-modified
superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in
neurons. Free Radic Biol Med. 2010; 49:548–558. [PubMed: 20493251]
10. Briggs RG, Fee JA. Further characterization of human erythrocyte superoxide dismutase.
Biochimica et Biophysica Acta (BBA) - Protein Struct. 1978; 537:86–99.
11. Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-superoxide dismutase, a
conjugate in search of exploitation. Adv Drug Deliv Rev. 2002; 54:587–606. [PubMed: 12052716]
12. Haun SE, Kirsch JR, Helfaer MA, Kubos KL, Traystman RJ. Polyethylene glycol-conjugated
superoxide dismutase fails to augment brain superoxide dismutase activity in piglets. Stroke. 1991;
22:655–659. [PubMed: 2028497]
13. Veronese FM, Caliceti P, Pastorino A, Schiavon O, Sartore L, Banci L, Scolaro LM. Preparation,
physico-chemical and pharmacokinetic characterization of monomethoxypoly(ethylene glycol)-
derivatized superoxide dismutase. J Control Release. 1989; 10:145–154.
14. Yoshida K, Burton GF, McKinney JS, Young H, Ellis EF. Brain and tissue distribution of
polyethylene glycol-conjugated superoxide dismutase in rats. Stroke. 1992; 23:865–869. [PubMed:
1595107]
15. Hood E, Simone E, Wattamwar P, Dziubla T, Muzykantov V. Nanocarriers for vascular delivery of
antioxidants. Nanomedicine (Lond). 2011; 6:1257–1272. [PubMed: 21929460]
16. Han J, Shuvaev VV, Muzykantov VR. Catalase and superoxide dismutase conjugated with platelet-
endothelial cell adhesion molecule antibody distinctly alleviate abnormal endothelial permeability
caused by exogenous reactive oxygen species and vascular endothelial growth factor. J Pharmacol
Exp Ther. 2011; 338:82–91. [PubMed: 21474567]
17. Shuvaev VV, Muzykantov VR. Targeted modulation of reactive oxygen species in the vascular
endothelium. J Control Release. 2011; 153:56–63. [PubMed: 21457736]
18. Shuvaev VV, Tliba S, Nakada M, Albelda SM, Muzykantov VR. Platelet-endothelial cell adhesion
molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress
caused by either extracellular or intracellular superoxide. J Pharmacol Exp Ther. 2007; 323:450–
457. [PubMed: 17712041]
19. Choi YJ, Lee JY, Chung CP, Park YJ. Cell-penetrating superoxide dismutase attenuates oxidative
stress-induced senescence by regulating the p53-p21(Cip1) pathway and restores osteoblastic
differentiation in human dental pulp stem cells. Int J Nanomedicine. 2012; 7:5091–5106.
[PubMed: 23049256]
20. Reukov V, Maximov V, Vertegel A. Proteins conjugated to poly(butyl cyanoacrylate)
nanoparticles as potential neuroprotective agents. Biotechnol Bioeng. 2011; 108:243–252.
[PubMed: 20939007]
21. Batrakova EV, Vinogradov SV, Robinson SM, Niehoff ML, Banks WA, Kabanov AV.
Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced
brain delivery. Bioconjug Chem. 2005; 16:793–802. [PubMed: 16029020]
Tong et al. Page 18













22. Yi X, Batrakova E, Banks WA, Vinogradov S, Kabanov AV. Protein conjugation with amphiphilic
block copolymers for enhanced cellular delivery. Bioconjug Chem. 2008; 19:1071–1077.
[PubMed: 18447367]
23. Price TO, Farr SA, Yi X, Vinogradov S, Batrakova E, Banks WA, Kabanov AV. Transport across
the blood-brain barrier of pluronic leptin. J Pharmacol Exp Ther. 2010; 333:253–263. [PubMed:
20053933]
24. Banks WA, Gertler A, Solomon G, Niv-Spector L, Shpilman M, Yi X, Batrakova E, Vinogradov S,
Kabanov AV. Principles of strategic drug delivery to the brain (SDDB): Development of anorectic
and orexigenic analogs of leptin. Physiol Behav. 2011; 105:145–149. [PubMed: 21669216]
25. Tong J, Luxenhofer R, Yi X, Jordan R, Kabanov AV. Protein modification with amphiphilic block
copoly(2-oxazoline)s as a new platform for enhanced cellular delivery. Mol Pharm. 2010; 7:984–
992. [PubMed: 20550191]
26. Luxenhofer R, Schulz A, Roques C, Li S, Bronich TK, Batrakova EV, Jordan R, Kabanov AV.
Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs.
Biomaterials. 2010; 31:4972–4979. [PubMed: 20346493]
27. Barz M, Luxenhofer R, Zentel R, Vicent MJ. Overcoming the PEG-addiction: well-defined
alternatives to PEG, from structure-property relationships to better defined therapeutics. Polym
Chem. 2011; 2:1900–1918.
28. Luxenhofer R, Han Y, Schulz A, Tong J, He Z, Kabanov AV, Jordan R. Poly(2-oxazoline)s as
polymer therapeutics. Macromol Rapid Commun. in print, DOI: 10.1002/marc.201200354.
29. Luxenhofer R, Sahay G, Schulz A, Alakhova D, Bronich TK, Jordan R, Kabanov AV. Structure-
property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphiles. J Control
Release. 2011; 153:73–82. [PubMed: 21513750]
30. Roe JA, Butler A, Scholler DM, Valentine JS, Marky L, Breslauer KJ. Differential scanning
calorimetry of Cu,Zn-superoxide dismutase, the apoprotein, and its zinc-substituted derivatives.
Biochemistry. 1988; 27:950–958. [PubMed: 2835081]
31. Das SK, Fanburg BL. Hyperoxia elevates Cu,Zn-superoxide dismutase of endothelial cells as
detected by a sensitive ELISA. Enzyme. 1992; 46:188–195. [PubMed: 1292928]
32. Tsogtbaatar G, Tachibana M, Watanabe K, Kim S, Suzuki H, Watarai M. Enzyme-linked
immunosorbent assay for screening of canine brucellosis using recombinant Cu-Zn superoxide
dismutase. J Vet Med Sci. 2008; 70:1387–1389. [PubMed: 19122412]
33. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;
145:182–195. [PubMed: 20226220]
34. Sahay G, Batrakova EV, Kabanov AV. Different internalization pathways of polymeric micelles
and unimers and their effects on vesicular transport. Bioconjug Chem. 2008; 19:2023–2029.
[PubMed: 18729494]
35. Tong J, Zimmerman MC, Li S, Yi X, Luxenhofer R, Jordan R, Kabanov AV. Neuronal uptake and
intracellular superoxide scavenging of a fullerene (C60)-poly(2-oxazoline)s nanoformulation.
Biomaterials. 2011; 32:3654–3665. [PubMed: 21342705]
36. Banks WA, Kastin AJ, Brennan JM, Vallance KL. Adsorptive endocytosis of HIV-1gp120 by
blood-brain barrier is enhanced by lipopolysaccharide. Exp Neurol. 1999; 156:165–171. [PubMed:
10192787]
37. Blasberg RG, Patlak CS, Fenstermacher JD. Selection of experimental conditions for the accurate
determination of blood--brain transfer constants from single-time experiments: a theoretical
analysis. J Cereb Blood Flow Metab. 1983; 3:215–225. [PubMed: 6841469]
38. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer
constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983; 3:1–7. [PubMed:
6822610]
39. Bullock J, Chowdhury S, Severdia A, Sweeney J, Johnston D, Pachla L. Comparison of results of
various methods used to determine the extent of modification of methoxy polyethylene glycol
5000-modified bovine Cupri-Zinc superoxide dismutase. Anal Biochem. 1997; 254:254–262.
[PubMed: 9417786]
40. Veronese FM, Sartore L, Schiavon O, Caliceti P. A comparative study of enzymatic, structural, and
pharmacokinetic properties of superoxide dismutase isolated from two sources and modified by
Tong et al. Page 19













monomethoxypolyethylene glycol using different methods of coupling. Ann N Y Acad Sci. 1990;
613:468–474. [PubMed: 2075997]
41. Banci L, Bertini I, Caliceti P, Monsu Scolaro L, Schiavon O, Veronese FM. Spectroscopic
characterization of polyethyleneglycol modified superoxide dismutase: 1H NMR studies on its
Cu2Co2 derivative. J Inorg Biochem. 1990; 39:149–159. [PubMed: 2166134]
42. Foreman MB, Coffman JP, Murcia MJ, Cesana S, Jordan R, Smith GS, Naumann CA. Gelation of
amphiphilic lipopolymers at the air-water interface: 2D analogue to 3D gelation of colloidal
systems with grafted polymer chains? Langmuir. 2002; 19:326–332.
43. Rehfeldt F, Tanaka M, Pagnoni L, Jordan R. Static and dynamic swelling of grafted poly(2-
alkyl-2-oxazoline)s. Langmuir. 2002; 18:4908–4914.
44. Shinoda T, Takagi A, Maeda A, Kagatani S, Konno Y, Hashida M. In vivo fate of folate-BSA in
non-tumor- and tumor-bearing mice. J Pharm Sci. 1998; 87:1521–1526. [PubMed: 10189259]
45. Katsumi H, Nishikawa M, Yamashita F, Hashida M. Development of polyethylene glycol-
conjugated poly-S-nitrosated serum albumin, a novel S-Nitrosothiol for prolonged delivery of
nitric oxide in the blood circulation in vivo. J Pharmacol Exp Ther. 2005; 314:1117–1124.
[PubMed: 15901798]
46. Khmelnitsky YL, Mozhaev VV, Belova AB, Sergeeva MV, Martinek K. Denaturation capacity: a
new quantitative criterion for selection of organic solvents as reaction media in biocatalysis. Eur J
Biochem. 1991; 198:31–41. [PubMed: 1645649]
47. Miyamoto M, Naka K, Shiozaki M, Chujo Y, Saegusa T. Preparation and enzymic activity of
poly[(N-acylimino)ethylene]-modified catalase. Macromolecules. 1990; 23:3201–3205.
48. Viegas TX, Bentley MD, Harris JM, Fang Z, Yoon K, Dizman B, Weimer R, Mero A, Pasut G,
Veronese FM. Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug
Chem. 2011; 22:976–986. [PubMed: 21452890]
49. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Factors affecting short-term and long-term
stabilities of proteins. Adv Drug Deliv Rev. 2001; 46:307–326. [PubMed: 11259845]
50. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous
solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res. 2003;
20:1325–1336. [PubMed: 14567625]
51. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol. 2007;
8:603–612. [PubMed: 17609668]
52. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003; 422:37–44.
[PubMed: 12621426]
53. Richter C, Gogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M, Walter P, Yaffee M.
Oxidants in mitochondria: from physiology to diseases. Biochimica et biophysica acta. 1995;
1271:67–74. [PubMed: 7599228]
54. Dikalov S, Griendling KK, Harrison DG. Measurement of reactive oxygen species in
cardiovascular studies. Hypertension. 2007; 49:717–727. [PubMed: 17296874]
55. Klyachko NL, Manickam DS, Brynskikh AM, Uglanova SV, Li S, Higginbotham SM, Bronich
TK, Batrakova EV, Kabanov AV. Cross-linked antioxidant nanozymes for improved delivery to
CNS. Nanomedicine. 2012; 8:119–129. [PubMed: 21703990]
56. Hu P, Tirelli N. Scavenging ROS: superoxide dismutase/catalase mimetics by the use of an
oxidation-sensitive nanocarrier/enzyme conjugate. Bioconjug Chem. 2012; 23:438–449. [PubMed:
22292618]
Tong et al. Page 20














Schematic representation of the synthesis of poly(2-oxazoline) (POx), the conjugation of
POx with SOD1 and the radiolabeling of SOD1-POx: The details of POx synthesis has been
reviewed elsewhere 28. For SOD1-POx conjugation, first, piperazine-terminated amphiphilic
POx copolymers were functionalized with a stable (DSS) or redox labile linker (DSP) to
yield N-hydroxysuccinimide terminated POx. Second, the reactive POx were conjugated
with the primay amines of SOD1 to yield SOD1-POx conjugates. SOD1-POx was
radioactively labeled using the chloramine-T method for in vivo study.
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Structures of POx used in the present study: (a) P(MeOx-b-BuOx); (b) P(EtOx-b-BuOx).
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Representative MALDI-ToF MS of (a) SOD1, (b) SOD1-(cc)-P(MeOx-b-BuOx) and (c)
SOD1-(cc)-P(EtOx-b-BuOx). The average molar mass and composition of each peak are
labeled. (m)SOD1: SOD1 monomer; (d)SOD1: SOD1 dimer; (tri)SOD1: SOD1 trimer;
(tetra)SOD1: SOD1 tetramer.
Tong et al. Page 24














Representative SDS-PAGE of SOD1 and SOD1-POx: L: ladder; S: SOD1; C1: SOD1-(cc)-
P(MeOx-b-BuOx); C2: SOD1-(cc)-P(EtOx-b-BuOx). The conjugates are marked by arrows.
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Representative far-UV CD spectra of SOD1 and SOD1-POx. All samples were dissolved in
PBS (pH 7.4) at 0.5 mg/mL as determined by MicroBCA assay.
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Volume-based size distributions of the particles in SOD1 and SOD1-POx solutions
determined by DLS at 25 °C. All samples were dissolved in PBS (pH 7.4) at 0.5 mg/mL and
sterile filtered (450 nm filter) prior to the measurements.
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Cytotoxicity of SOD1, SOD1-POx and PEG5000-b-PLL50 in CATH.a neuronal cells. Cells
were incubated with 80 μg/mL of SOD1 or SOD1-polymer conjugates for 1 h, 6 h or 24 h in
full medium and were allowed to grow for another 48 h. Cytotoxicity was determined by the
cell counting assay. Data are means ± SEM (n=6).
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(a) Cellular uptake of SOD1, SOD1-PEG and SOD1-POx in CATH.a neuronal cells. Cells
were incubated with 80 μg/mL of SOD1 or SOD1-polymer conjugates for 1 to 24 h in
serum-free medium. Total cellular uptake was determined by SOD1 ELISA and normalized
to the total cell protein determined by MicroBCA assay. Data are means ± SEM (n = 3), *
p<0.05 and ** p<0.01. (b) Cellular uptake of fluorescently-labeled SOD1 and SOD1-POx
obtained by CLSM. Cells were incubated with 80 μg/mL of SOD1 or SOD1-POx for 1-24 h
in serum-free conditions and imaged by CLSM.
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Intracellular distribution and endocytosis of fluorescently-labeled SOD1-POx in CATH.a
neuronal cells. (a) Intracellular distribution of SOD1-(cc)-P(EtOx-b-BuOx). Cells were
incubated with 80 μg/mL of SOD1-(cc)-P(EtOx-b-BuOx) for 6 h and stained with Hoechst
33342, MitoTracker®, LysoTracker® or ER-Tracker® for 30 min. (b) Quantitative
colocalization analysis of SOD1-(cc)-P(EtOx-b-BuOx) with organelle-specific dyes. (c)
Colocalization of SOD1-(cc)-P(EtOx-b-BuOx) with specific endocytosis markers Tf and
CTB. Cells were co-incubated with 80 μg/mL of SOD1-(cc)-P(EtOx-b-BuOx) and Alexa
Fluor® 488-conjugated Tf or CTB for 6 h. (d) Quantitative colocalization analysis of SOD1-
(cc)-P(EtOx-b-BuOx) with Tf and CTB. (e) Inhibition of the cellular uptake of SOD1-(cc)-
P(EtOx-b-BuOx) by hypertonic sucrose and MBCD as determined by CLSM. Cells were
pre-treated with hypertonic 0.4 M sucrose or 4 mM MBCD for 30 min and then co-
incubated with 80 μg/mL of SOD1-(cc)-P(EtOx-b-BuOx) for 6 h. The quantitative mean
fluorescence intensity was analyzed and compared with non-treated controls. Data are
presented as means ± SEM (n=10-15), ** p<0.01.
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Intracellular SOD activity of SOD1, SOD1-PEG and SOD1-(cc)-P(EtOx-b-BuOx) in
CATH.a neuronal cells. Cells were incubated with 80 μg/mL of SOD1 or SOD1-polymer
conjugates for 12 h in serum-free conditions. SOD activities of the treated and non-treated
cell lysate were determined by luminol-based chemiluminescence assay. HX-XO system
was used as the superoxide source. (a) Chemiluminescence signals of the tested samples
immediatedly after mixing of reagents and cell lysates or buffer (for control). Data are
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presented as means ± SEM (n=3), ** p<0.01. (b) Representative curves of the time decay of
the chemiluminescence after mixing for the control, non-treated (blank) and SOD1-(cc)-
P(EtOx-b-BuOx)-treated cell lysate.
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Intracellular superoxide scavenging of SOD1, SOD1-PEG and SOD1-(cc)-P(EtOx-b-BuOx)
in CATH.a neuronal cells. Cells were incubated with 80 μg/mL of SOD1 or SOD1-polymer
conjugates for 12 h in serum-free conditions. CMH was added as the cell-permeable,
superoxide-sensitive spin probe. Superoxide was generated by stimulating neurons with 100
nM of Ang II. CMH radical signal was recorded by EPR spectroscopy and normalized to
total cell number. (a) Normalized EPR signals of the tested samples. Data are presented as
means ± SEM (n=3), * p<0.05 and ** p<0.01. (b) Representative normalized EPR spectra of
the negative control (blank), positive control (with Ang II) and SOD1-(cc)-P(EtOx-b-BuOx)
treated cells.
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PK of radiolabeled SOD1 and SOD1-(cc)-P(EtOx-b-BuOx) in mice. (a) Serum clearance
of 125I-SOD and 125I-SOD-(cc)-P(EtOx-b-BuOx) with co-injected 131I-albumin following
i.v. injection. (b) The initial distribution phase (0-60 min) of 125I-SOD1 and 125I-SOD1-
(cc)-P(EtOx-b-BuOx) after injection was linear, and the half-time disappearance from blood
was 28.39 min for SOD1-(cc)-P(EtOx-b-BuOx) and 15.94 min for SOD1. The clearance of
SOD1 is significantly faster than that of SOD1-(cc)-P(EtOx-b-BuOx) (p< 0.001).
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BBB transport and brain uptake of radiolabeled SOD1-(cc)-P(EtOx-b-BuOx) in mice. (a)
and (b) Multiple-time regression analysis of (a) 125I-SOD1 and (b) 125I-SOD1-(cc)-P(EtOx-
b-BuOx) transport across the BBB. 131I-albumin was co-injected in each group and the brain
serum ratio of 131I-albumin was subtracted from that of 125I-SOD1 or 125I-SOD1-(cc)-
P(EtOx-b-BuOx) to correct the vascular space of each individual animal. For SOD1-POx,
the unidirectional influx rate, Ki = 0.052 ±0.006 μL/g·min; vascular distribution, Vi = 2.121
±0.05 μL/g (r = 0.86, p <0.0001; n =1 ~2 mice/time point). In comparison, there was no
linear relation between the brain/serum ratio of SOD1 and its exposure time, indicating no
entry of SOD1 into the brain. (c) Brain uptake of 125I-SOD1-(cc)-P(EtOx-b-BuOx)
following i.v. injection. The results were corrected for the distribution volume in the brain of
SOD1-POx at t = 0. The maximal value after 4 h following i.v. injection was estimated by a
one-site binding model to approach 0.08%ID/g. (d) Nonradioactive SOD1-(cc)-P(EtOx-b-
BuOx) (5 μg/mouse) did not inhibit the brain/serum ratio of 125I-(cc)-P(EtOx-b-BuOx) at 60
min after i.v. injection. No statistically significant difference was observed between animals
receiving 125I-SOD1-POx and animals receiving 125I-SOD1-POx plus SOD1-POx (n=7).(e)
Distribution of 125I-SOD1-(cc)-P(EtOx-b-BuOx) in brain parenchyma and capillary
fractions. The vascular space was washed free of blood at 60 min following i.v. injection.
The brain parenchyma/serum ratio was significantly higher than the capillary/serum ratio
(5.56 ± 0.97 μL/g vs 2.78 ±0.40 μL/g) (* p < 0.05; n =3).
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Tissue distribution of 125I-SOD1-(cc)-P(EtOx-b-BuOx) and co-injected 131I-SOD1 at 60
min following i.v. injection. Results were interpreted as tissue/serum ratio in μL per gram of
tissue (n=5). The tissue/serum ratio of SOD1-POx in brain, heart, liver, spleen and lung
were all significantly higher than that of SOD1 (* p<0.05), whereas for kidney, muscle, and
stomach no significant difference was observed.
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Table 2
Molecular characteristics of SODI-POx conjugates.
Conjugates
a Linker Modification degree
b




SOD1-(cc)-P(MeOx-b-BuOx) DSS 2.2 36 88.65
SOD1-(ss)-P(MeOx-b-BuOx) DSP 3.5 47 N/A
SOD1-(cc)-P(EtOx-b-BuOx) DSS 2.5 34 88.38
SOD1-(ss)-P(EtOx-b-BuOx) DSP 2.3 31 N/A
a
Here “-(cc)-” and “-(ss)-” designate SOD1-POx conjugates containing stable and degradable bonds formed by DSS and DSP, respectively.
b
Counting per SOD1 dimer as determined by TNBS assay.
c




Tm of unmodified SOD1 is 92.14 °C.
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